NCT01919684View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

LGD-6972

DRUG

Placebo (Captisol®)

Trial Locations (1)

45227

Medpace Clinical Pharmacology, Cincinnati

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Beckloff Associates, Inc.

INDUSTRY

collaborator

Medpace, Inc.

INDUSTRY

lead

Ligand Pharmaceuticals

INDUSTRY

NCT01919684 - Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter